Lpath Announces Proposed Public Offering of Common Stock

Lpath Announces Proposed Public Offering of Common Stock 
SAN DIEGO, CA -- (Marketwire) -- 12/13/12 --  Lpath, Inc. (NASDAQ:
LPTN) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. The offering is
subject to market conditions and there can be no assurance as to
whether or when the offering may be complete, or as to the actual
size or terms of the offering. Summer Street Research Partners is
acting as sole book-running manager for the offering. 
The securities described above are being offered by Lpath pursuant to
a shelf registration statement previously filed with and declared
effective by the Securities and Exchange Commission ("SEC") on
November 14, 2012. A preliminary prospectus supplement relating to
the offering will be filed with the SEC and will be available on the
SEC's website located at www.sec.gov.  
Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from Summer
Street Research Partners, Attention: Prospectus Department, at 101
Arch Street, Boston, MA 02110, or via telephone at (617) 532-6433, or
via email at bryanm@ssrp.com. 
This press release does not and shall not constitute an offer to sell
or the solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. 
About Lpath
 San Diego-based Lpath, Inc. is focused on developing
lipid-targeted therapeutics, an emerging field of medicine that
targets bioactive signaling lipids for the treatment of human
disease. The company has developed three drug candidates: iSONEP(TM)
is currently in a Phase 2 trial for wet AMD; ASONEP(TM) is scheduled
to begin a Phase 2 trial in Renal Cell Carcinoma patients; and
Lpathomab is a preclinical drug candidate.  
About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description
of historical facts are forward-looking statements. These include
statements regarding the Company's proposed public offering of its
common stock. Actual results may differ materially from those set
forth in this press release due to the risks and uncertainties
inherent in the Company's business, including, without limitation:
the results of the Company's pre-clinical testing and its clinical
trials may not support either further clinical development or the
commercialization of its drug candidates; the Company may not
successfully complete additional clinical trials for its product
candidates on a timely basis, or at all; the Company may fail to
obtain required governmental approvals for any its drug candidates;
the Company has a history of net losses and may never achieve or
maintain profitability; the Company may not be successful in
maintaining its commercial relationship with Pfizer Inc.; and the
Company may not be able to secure the funds necessary to support its
preclinical- and clinical-development plans. More detailed
information about the risk factors and uncertainties that may affect
the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission (the
"SEC"), including its Annual Report on Form 10-K, its Quarterly
Reports on Form 10-Q and its other filings with the SEC. These
documents may be read free of charge on the SEC's website at
www.sec.gov. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 
Lpath, Inc.
Scott R. Pancoast 
President & CEO 
(858) 926-3200 
spancoast@Lpath.com  
Lpath Investor Relations
Liolios Group, Inc. 
(949) 574-3860
Ron Both: ron@liolios.com
Geoffrey Plank: geoffrey@liolios.com
lptn@liolios.com
 
 
Press spacebar to pause and continue. Press esc to stop.